<DOC>
	<DOCNO>NCT01286012</DOCNO>
	<brief_summary>The purpose study compare clinical safety efficacy SFP spar need erythropoiesis stimulate agent ( ESAs ) require maintain hemoglobin ( hgb ) level chronic hemodialysis subject receive SFP via dialysate versus subject receive conventional dialysate without iron .</brief_summary>
	<brief_title>Continuous Soluble Ferric Pyrophosphate ( SFP ) Iron Delivery Via Dialysate Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>Main 1 . Male female subject ≥ 18 year age . 2 . Endstage renal disease undergoing maintenance hemodialysis 3 4 time week least 4 month expect remain schedule able complete study . Subjects cadaveric transplant list need exclude reason unless identify donor . 3 . Mean Hgb range ≥ 9.5 ≤ 12.0 g/dL screening . 4 . The difference maximum minimum Hgb value screen exceed 1.0 g/dL . 5 . Mean ferritin ≥ 200 ≤ 1000 µg/L screen . 6 . Mean TSAT ≥ 15 % ≤ 40 % screening . 7 . Any serum albumin measure 2 month precede randomization must ≥ 3.0 g/dL . 8 . Prescribed ESA dose remain range ≥ 4,000 ≤ 45,000 U/week epoetin ≥ 12.5 ≤ 200 µg/week darbepoetin 6 week precede randomization . 9 . Required IV iron time 6 month precede randomization . Main 1 . Vascular access dialysis catheter . 2 . During 6 month prior randomization , infection vascular access use time randomization . 3 . Received total &gt; 600 mg IV iron 6 week prior randomization . 4 . Received amount IV oral iron 2 week prior randomization . 5 . Change prescribe ESA dose : 1 . Any change prescribe ESA dose within 4 week prior randomization . 2 . The prescribed ESA dose time randomization &gt; 25 % high low prescribe dose 6 week prior randomization . 3 . Change prescribed type ESA ( e.g. , epoetin vs. darbepoetin ) route administration within 6 week prior randomization . 6 . Actual ESA dosing miss withheld cumulative total ≥ 1 week reason 6 week prior randomization . 7 . Known cause anemia anemia attributable renal disease ( e.g. , sickle cell disease , thalassemia , pure red cell aplasia , hemolytic anemia , myelodysplastic syndrome , etc . ) 8 . Scheduled kidney transplant donor identify transplant schedule . 9 . Known ongoing inflammatory disorder ( Chronic Kidney Disease ) , systemic lupus erythematosus , rheumatoid arthritis , collagenvascular disease , etc . 11 . Known active tuberculosis , fungal , viral , parasitic infection require antimicrobial therapy anticipate require antimicrobial therapy patient 's participation study . Subjects hepatitis C , absence cirrhosis , exclude participation study Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level 2 time upper limit normal consistent basis 2 month precede randomization . 12 . Occult tuberculosis require prophylactic treatment antitubercular drug ( ) overlap patient 's participation study . 13 . Cirrhosis liver base histological criterion clinical criterion ( e.g. , presence ascites , esophageal varix , spider nevus , history hepatic encephalopathy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>End Stage Renal Disease , Hemodialysis , SFP</keyword>
</DOC>